Noom, a digital health company for chronic disease prevention, will begin offering oral medications for weight loss through its Noom Med program, it announced Thursday.

周四，Noom宣布，一家致力于慢性病预防的数字健康公司将通过其Noom Med计划开始提供口服减肥药物。

New York City-based Noom helps people build healthy habits through psychological tools like food tracking, coaching and community. Through Noom Med, patients get access to one-on-one messaging with weight loss clinicians, medication prescriptions, a community of patients, medication management and educational content.

总部位于纽约市的Noom通过食物追踪、辅导和社区等心理工具帮助人们养成健康习惯。通过Noom Med，患者可以与减肥临床医生、药物处方、患者社区、药物管理和教育内容进行一对一的信息交流。

They can also get prescriptions for GLP-1s when appropriate..

他们也可以在适当的时候获得GLP-1的处方。。

With the inclusion of oral medications for weight loss, Noom Med can support those who have a needle aversion or have a lower body mass index than indicated for GLP-1s. The first oral weight loss medication offered through Noom is Metformin, which is often used for type 2 diabetes but can be prescribed off-label when appropriate for weight loss.

随着口服减肥药物的加入，Noom Med可以支持那些厌恶针头或体重指数低于GLP-1的人。通过Noom提供的第一种口服减肥药物是二甲双胍，它通常用于2型糖尿病，但在适合减肥时可以在标签外开具。

It helps reduce appetite and increases insulin sensitivity. .

它有助于减少食欲并增加胰岛素敏感性。。

Exclusive

独家

Heard at HLTH 2024: Insights from Innovative Healthcare Executives

在HLTH 2024上听到：来自创新医疗保健高管的见解

Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.

来自Imagine360、Verily、BrightInsight、Lantern和Rhapsody的高管分享了他们降低医疗成本和促进数字化转型的方法。

By MedCity News

By√9；：<9MedCity News

Noom is providing Metformin to consumers as a 500mg daily tablet for $29 for the first month, and then $89/month for a three-month recurring subscription. Comparatively, the Noom GLP-1Rx plan gives users access to compounded semaglutide starting at $149/month, regardless of insurance coverage. Through Noom Med, users can get brand-name GLP-1s like Ozempic starting at $69/month plus the out-of-pocket costs for the medication, which depends on insurance coverage..

Noom向消费者提供每日500毫克的二甲双胍片剂，第一个月的价格为29美元，三个月的定期订阅价格为89美元/月。相比之下，Noom GLP-1Rx计划允许用户以每月149美元的价格获得复合semaglutide，而不考虑保险范围。通过Noom Med，用户可以获得品牌GLP-1s，如Ozempic，起价为69美元/月，外加药物的自付费用，这取决于保险范围。。

“With the addition of oral medications, we provide a meaningful weight loss treatment option at a lower price. Metformin is widely available as a generic medication, making it an affordable option for people who need it. … GLP-1 injections may not be the right solution for everyone seeking to achieve better health and longevity through weight loss.

“随着口服药物的增加，我们以较低的价格提供了一种有意义的减肥治疗选择。二甲双胍作为非专利药物被广泛使用，使其成为需要它的人的负担得起的选择……GLP-1注射可能不是每个寻求通过减肥获得更好健康和长寿的人的正确解决方案。

Adding oral medication opens up another avenue for our customers to experience powerful meds with the powerful companion of Noom’s behavior change program,” said Geoff Cook, CEO at Noom, in an email..

Noom首席执行官杰夫·库克（GeoffCook）在一封电子邮件中说：“添加口服药物为我们的客户开辟了另一条途径，让他们与Noom的行为改变计划的强大伙伴一起体验强大的药物。”。。

To access oral medications, Noom members fill out an intake survey and then connect with a clinician who reviews their results and prescribes Metformin if appropriate. The medication is then shipped directly to the member within seven days. They also have access to Noom Med’s other features, including asynchronous telehealth, care coordinators and one-on-one coaching..

为了获得口服药物，Noom成员填写了一份摄入量调查，然后与临床医生联系，临床医生会审查他们的结果，并在适当的情况下开具二甲双胍。然后在七天内将药物直接运送给会员。他们还可以访问Noom Med的其他功能，包括异步远程保健、护理协调员和一对一辅导。。

Cook said that Noom’s goal in offering oral medications is to “open up affordable access to empower people to live better longer.” He added that it’s important to have serious dialogue on strategies to lower prescription drug costs in the U.S., noting that U.S. drug prices are 2.5 times higher on average than other high-income countries..

库克说，努姆提供口服药物的目标是“开放负担得起的渠道，使人们能够活得更长。”他补充说，重要的是就降低美国处方药成本的战略进行认真对话，并指出美国的药品价格平均比其他高收入国家高2.5倍。。

Sponsored Post

赞助帖子

The Funding Model for Cancer Innovation is Broken — We Can Fix It

癌症创新的资助模式被打破了-我们可以修复它

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

缩小癌症健康公平差距需要通过新的资助方法实现医学突破。

By Eve McDavid - CEO of Mission-Driven Tech

作者Eve McDavid，任务驱动技术公司首席执行官

“I propose Congress empower the FDA to maintain a public High-Cost Drug Database of medications that are priced in the U.S. at levels 200% or more above the global average,” he said. “If a drug is listed in this database, FDA-regulated 503B outsourcing facilities would be empowered to manufacture compounded versions of these high-cost drugs, providing a market-driven solution to the current problem.”.

。“如果一种药物被列入该数据库，FDA监管的503B外包设施将被授权制造这些高成本药物的复合版本，为当前问题提供市场驱动的解决方案。”。

Other companies offering access to weight loss medications include WeightWatchers and LifeMD.

其他提供减肥药物的公司包括WeightWatchers和LifeMD。

Photo: Jason Dean, Getty Images

照片：杰森·迪恩，盖蒂图片社

Topics

主题

GLP-1

GLP-1

Noom

新

weight loss drugs

减肥药

MedCity News Daily Newsletter

MedCity新闻每日通讯

Sign up and get the latest news in your inbox.

注册并在收件箱中获取最新消息。

Enter your email address

输入您的电子邮件地址

Subscribe Now

立即订阅

We will never sell or share your information without your consent. See our privacy policy.

未经您同意，我们绝不出售或共享您的信息。请参阅我们的隐私政策。

More from MedCity News

更多来自MedCity新闻

Belgian Sleep Medicine Company Begins Providing Care In The US Through New Acquisition

比利时睡眠医学公司通过新收购开始在美国提供护理

ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More

ASH 2024回顾：多发性骨髓瘤、细胞疗法、镰状细胞病等的发展

Why Expanding Access to Alternative Drug-free Pain Management May be the Key to Improving Chronic Pain Patient Outcomes

为什么扩大替代无药物疼痛管理的机会可能是改善慢性疼痛患者预后的关键

The Hidden Dangers of AI Confidence Scores in Healthcare

人工智能信心评分在医疗保健中的隐患